Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Leo International Precision Health AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten VerbreitungLeo International Precision Health AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
- Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress UpdateOslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its financial results for the third quarter of 2026 on Thursday, 5 November 2026.
- Akiram TherapeuticsAkiram Therapeutics: First clinical results from AKIR001 to be presented at EANM 2026Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, announces that the first clinical data from the ongoing Phase I trial of its lead drug candidate 177Lu-AKIR001 will be presented at the EANM 2026 Congress in Vienna, October 17-21....
- The Rosen Law Firm PAROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Hims & Hers (HIMS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/1/2026
- Robbins LLPRobbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class ActionShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ: GUTS) securities between January 13, 2025 and January...
- MemorialCareNationally Recognized Cardiac Surgeon Anthony D. Caffarelli, M.D., Joins MemorialCare as Chief of Cardiac Surgery, MemorialCare Heart & Vascular InstituteSouthern California physician leader returns to Long Beach and Orange County, where his medical career began, to help advance cardiovascular care across MemorialCare. — MemorialCare—a leading nonprofit integrated health system in...
- HmediumFrost & Sullivan Released the 2026 Global Gene Therapy Industry Development Blue BookFrost & Sullivan officially released the 2026 Global Gene Therapy Industry Development Blue Book in October 2026, in collaboration with industry partners. The report systematically examines the industry's development history, core technology classifications, policy and capital market dynamics, upstream and downstream value chains, bottlenecks in viral vector manufacturing, clinical progress across key indications, reimbursement pathways, and...
- LabConnectGCCL and LabConnect Sign MOU to Expand Global Clinical Trial CollaborationLinking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution — GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today...
- Awareness Marketing Management DWC LLCSaudi German Hospital Dubai Launches Mental Health and Wellness Center for Children and AdolescentsSaudi German Hospital Dubai has launched the Saudi German Mental Health & Wellness Hub, unveiled at an evening event at Raffles The Palm on 9 October 2026. The Hub is designed to end the fragmented experience many families face when navigating mental healthcare by bringing psychiatrists, psychologists and relevant hospital specialties together around a single, shared plan for each patient.To view an enhanced version of this...
- Castle Biosciences, Inc.ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's EsophagusStudies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative...
- Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot UlcersOrganogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE1, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly®AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The trial achieved its primary endpoint, and the results published in the Journal of Wound Care demonstrate statistically significant improvements in wound closure at 12 weeks among patients treated with PuraPly®AM plus SoC, providing clinical evidence supporting the use of PuraPly®AM in one of the most costly and difficult-to-treat chronic wound populations.